

## **ANNEX I**

### **SUMMARY OF PRODUCT CHARACTERISTICS**

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Dalmazin, 75 micrograms/ml, solution for injection for cattle and pigs (AT, BE, DE, IE, IT, LU, NI).

Reprosténol, 75 micrograms/ml, solution for injection for cattle and pigs (FR).

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

#### Active substance:

d-cloprostenol .....75 µg

#### Excipients:

| Qualitative composition of excipients and other constituents | Quantitative composition if that information is essential for proper administration of the veterinary medicinal product |
|--|---|
| Ethanol  |   |
| Chlorocresol   | 1 mg  |
| Sodium hydroxide   |   |
| Citric acid  |   |
| Water for injections   |   |

Clear, colourless solution for injection with no visible particles.

### 3. CLINICAL INFORMATION

#### 3.1 Target species

Cattle (cows) and pigs (sows and young females).

#### 3.2 Indications for use for each target species

##### Cows

Indications for reproduction: synchronisation or induction of oestrus. Induction of parturition after day 270 of gestation.

Therapeutic indications: ovarian dysfunction (persistent corpus luteum, luteal cyst), endometritis/pyometra, delayed uterine involution, induction of abortion in the first half of pregnancy and expulsion of mummified foetuses.

##### Sows and young females

Indications for reproduction: induction of parturition.

#### 3.3 Contraindications

Do not use in pregnant females, unless it is desirable to induce parturition or induction of abortion.

Do not use in sows which are expected to have a distocic parturition due to abnormal position of the foetus, mechanical obstruction, etc.

Do not use in animals suffering cardiovascular or respiratory diseases.

Do not use in animals with spastic diseases of the respiratory or gastrointestinal tract.

### 3.4 Special warnings

None.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

As with parenteral administration of any substance, basic antiseptic rules should be observed.

The injection site must be thoroughly cleaned and disinfected in order to reduce the risk of infection with anaerobic bacteria.

Induction of labour before the 111th day of gestation may cause mortality in piglets and an increase in the number of sows that require manual assistance.

Do not administer by intravenous route.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Prostaglandins of the F<sub>2α</sub> type can be absorbed through the skin and may cause bronchospasm or miscarriage.

Care should be taken when handling the product to avoid self-injection or skin contact.

Pregnant women, women of child-bearing age, asthmatics and people with bronchial or other respiratory problems, should avoid contact with, or wear disposable plastic gloves when administering the product.

Accidental spillage on the skin should be washed off immediately with soap and water.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Should shortness of breath result from accidental inhalation or injection, seek urgent medical advice and show the doctor this warning.

Do not eat, drink or smoke while handling the product.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Cattle (cows) and pigs (sows and young females):

|                        |  |
|------------------------|--|
| Undetermined frequency | Injection site infection <sup>a</sup> .<br>Injection site swelling <sup>a</sup> .<br>Crepitus <sup>a</sup> .<br>Retained placenta <sup>b</sup> .<br>Behavioural changes <sup>c</sup> . |
|------------------------|--|

<sup>a</sup> due to anaerobic infection, especially after intramuscular injection in cows.

<sup>b</sup> dependent on the time of treatment relative to the date of conception, the incidence in cows may be increased.

<sup>c</sup> similar to those changes associated with natural farrowing in sows usually ceasing within one hour.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing

authorisation holder or its local representative or the national competent authority via the national reporting system. See package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy and lactation:

Do not use in gestating animals unless it is desirable to induce parturition or therapeutic induction of abortion.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Do not administer the treatment together with non-steroidal anti-inflammatory drugs since they inhibit endogenous prostaglandin synthesis.

The activity of other oxytocic agents can be increased after the administration of cloprostenol.

### **3.9 Administration routes and dosage**

For intramuscular use.

#### Cows

Administer 2 ml of the veterinary medicinal product, equivalent to 150 micrograms of d-cloprostenol/animal by intramuscular route. Repeat after 11 days for the synchronisation of oestrus. The dose of 2 ml equivalent to 150 micrograms of d-cloprostenol/animal by intramuscular route can be repeated for the induction of oestrus and for the treatment of ovarian dysfunction, endometritis/pyometra and delayed uterine involution.

In particular:

- Induction of oestrus (also in cows showing weak or silent heat): administer the veterinary medicinal product after having established the presence of a corpus luteum (6-18<sup>th</sup> day of the cycle); heat usually appears within 48-60 hours. Proceed, therefore, with insemination 72-96 hours after injection. If oestrus is not evident, administration of the product needs to be repeated 11 days after the first injection.
- Synchronisation of oestrus: administer the veterinary medicinal product twice, with an interval of 11 days between each dose. Proceed therefore with two artificial inseminations at intervals of 72 and 96 hours from the second injection.
- Induction of parturition: administer the veterinary medicinal product after 270 days of pregnancy. Birth usually results within 30-60 hours of treatment.
- Mummified foetus: expulsion of the foetus is observed within 3-4 days after administration of the veterinary medicinal product.
- Induction of abortion: administer the veterinary medicinal product in the first half of pregnancy.
- Ovarian dysfunction (persistent corpus luteum, luteal cysts): administer the veterinary medicinal product, then proceed to inseminate at the first oestrus after injection. If oestrus is not evident, conduct a further gynaecological examination, and repeat the injection 11 days after the first administration. Insemination must always be carried out 72-96 hours after injection.
- Endometritis, pyometra: administer the veterinary medicinal product and if necessary repeat the treatment after 10-11 days.
- Delayed uterine involution: administer the veterinary medicinal product and, if considered necessary, carry out one or two successive treatments at 24 hour intervals.

#### Sows and young females

Administer 1 ml of the veterinary medicinal product, equivalent to 75 micrograms of d-cloprostenol/animal, by intramuscular route, not earlier than 112 days of pregnancy. Repeat after 6 hours. Alternatively, 20 hours after the initial dose of the veterinary medicinal product, a myometrial stimulant (oxytocin or carazolol) may be administered.

Following the protocol of the double administration, approximately 70-80% of the animals will give birth during the interval between 20 and 30 hours after the first administration.

As with every prostaglandin-based product, injection in contaminated skin areas is to be avoided in order to reduce the risk of infection with anaerobic bacteria.

The injection site must be thoroughly cleaned and disinfected before administration.

The closures should not be punctured more than 20 times.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

At 10 times the therapeutic dose, no adverse reactions were reported. In general, a large overdose could result in the following symptoms: increased pulse and breathing rate, bronchoconstriction, increased body temperature, increased amounts of loose faeces and urine, salivation and vomiting. As no specific antidote has been identified, in the case of overdose, symptomatic therapy is advisable. An overdose will not accelerate corpus luteum regression.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Meat and offal:

|        |           |
|--------|-----------|
| cattle | Zero days |
| pigs   | 1 day     |

Milk: Zero hours

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QG02AD90**

### **4.2 Pharmacodynamics**

The veterinary medicinal product is a sterile aqueous solution containing 75 micrograms/ml of dextrorotatory cloprostenol, a synthetic analogue of the prostaglandin  $F_{2\alpha}$ .

d-cloprostenol, the dextrorotatory enantiomer, constitutes the biologically active component of the racemic cloprostenol molecule and results in an approximate 3.5-fold increase in activity.

Administered in the luteal phase of the oestrus cycle, d-cloprostenol induces functional and morphological regression of the corpus luteum (luteolysis) resulting in a sharp fall in progesterone levels. The increased release of the follicle stimulating hormone (FSH), induces the follicular maturation followed by signs of oestrus and by ovulation.

### **4.3 Pharmacokinetics**

Pharmacokinetic studies demonstrate a rapid absorption of d-cloprostenol. The peak blood level is reached a few minutes following intramuscular administration, as well as a rapid diffusion to the ovaries and uterus, the organs in which the maximum concentration is reached 10-20 minutes after administration.

Following intramuscular administration of 150 micrograms of d-cloprostenol in the cows, the peak plasma level ( $C_{max}$ ) of 1.4 micrograms/l is reached after approximately 90 minutes, while the elimination half life ( $t_{1/2\beta}$ ) is in the order of 1 hour 37 minutes. In sows, a  $C_{max}$  of approximately 2

micrograms/l is observed between 30 and 80 minutes following administration of 75 micrograms d-cloprostenol, with an elimination half life in the order of 3 hours 10 minutes.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf life after first opening the immediate packaging: 28 days.

### **5.3 Special precautions for storage**

Do not store above 25 °C

### **5.4 Nature and composition of immediate packaging**

2 ml, 10 ml, 20 ml vials in glass type I or type II, closed with a chlorobutyl rubber stopper with an aluminium overseal in a cardboard or an aluminium box.

Package sizes:

Cardboard box with 1 vial of 2 ml + syringe

Cardboard box with 15 vials of 2 ml

Cardboard box with 60 vials of 2 ml

Cardboard box with 1 vial of 10 ml

Cardboard box with 10 vials of 10 ml

Cardboard box with 1 vial of 20 ml

Aluminium box with 5 vials of 20ml

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

FATRO S.p.A.

## **7. MARKETING AUTHORISATION NUMBER(S)**

|                          |                               |
|--------------------------|-------------------------------|
| 1 vial of 2 ml + syringe | Marketing Authorisation No. : |
| 15 vials of 2 ml         | Marketing Authorisation No. : |
| 60 vials of 2 ml         | Marketing Authorisation No. : |
| 1 vial of 10 ml          | Marketing Authorisation No. : |
| 10 vials of 10 ml        | Marketing Authorisation No. : |
| 1 vial of 20 ml          | Marketing Authorisation No. : |
| 5 vials of 20ml          | Marketing Authorisation No. : |

## **8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: {DD/MM/YYYY}

## **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

MM/YYYY

## **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database.  
(<https://medicines.health.europa.eu/veterinary>).

**ANNEX III**

**LABELLING AND PACKAGE LEAFLET**



## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

Cardboard box:  
1 x 2 ml vial + syringe  
15 x 2 ml vials  
60 x 2 ml vials  
1 x 10 ml vial  
10 x 10 ml vials  
1 x 20 ml vial  
Aluminium box  
5 x 20 ml vials

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Dalmazin, 75 micrograms/ml, solution for injection for cattle and pigs (AT, BE, DE, IE, IT, LU, NI).

Reprosténol, 75 micrograms/ml, solution for injection for cattle and pigs (FR).

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains d-cloprostenol 75 µg

**3. PACKAGE SIZE**

1 x 2 ml + syringe  
15 x 2 ml  
60 x 2 ml  
1 x 10 ml  
10 x 10 ml  
1 x 20 ml  
5 x 20 ml

**4. TARGET SPECIES**

Cattle (cows) and pigs (sows and young females).

**5. INDICATIONS**

--- --- ---

**6. ROUTES OF ADMINISTRATION**

For intramuscular use.

**7. WITHDRAWAL PERIODS**

Withdrawal period:

Meat and offal:

cattle Zero days

pigs 1 day

Milk: Zero hours

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days.

Use by \_\_\_\_\_

**9. SPECIAL STORAGE PRECAUTIONS**

Do not store above 25 °C.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

To be supplied only on veterinary prescription.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

FATRO S.p.A.

**14. MARKETING AUTHORISATION NUMBERS**

|                          |                              |
|--------------------------|------------------------------|
| 1 vial of 2 ml + syringe | Marketing Authorisation No.: |
| 15 vials of 2 ml         | Marketing Authorisation No.: |
| 60 vials of 2 ml         | Marketing Authorisation No.: |
| 1 vial of 10 ml          | Marketing Authorisation No.: |
| 10 vials of 10 ml        | Marketing Authorisation No.: |
| 1 vial of 20 ml          | Marketing Authorisation No.: |
| 5 vials of 20 ml         | Marketing Authorisation No.: |

**15. BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**

10 ml vial - 20 ml vial

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Dalmazin, 75 micrograms/ml, solution for injection for cattle and pigs (AT, BE, DE, IE, IT, LU, NI).

Reprosténol, 75 micrograms/ml, solution for injection for cattle and pigs (FR).

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains d-cloprostenol 75 µg

**3. TARGET SPECIES**

Cattle (cows) and pigs (sows and young females).

**4. ROUTES OF ADMINISTRATION**

Read the package leaflet before use.

For intramuscular use.

**5. WITHDRAWAL PERIODS**

Withdrawal period:

Meat and offal:

cattle Zero days

pigs 1 day

Milk: Zero hours

**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days.

Use by \_\_\_\_\_

**7. SPECIAL STORAGE PRECAUTIONS**

Do not store above 25 °C.

**8. NAME OF THE MARKETING AUTHORISATION HOLDER**

FATRO S.p.A.

**9. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

2 ml vial

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Dalmazin

Reprosténol

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

d-cloprostenol 75 µg/ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached use within 28 days

Use by \_\_\_\_\_

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

Dalmazin, 75 micrograms/ml, solution for injection for cattle and pigs (AT, BE, DE, IE, IT, LU, NI).

Reprosténol, 75 micrograms/ml, solution for injection for cattle and pigs (FR).

### 2. Composition

Each ml contains:

**Active substance:** d-cloprostenol 75 µg

**Excipients:** chlorocresol 1 mg

Clear, colourless solution for injection with no visible particles.

### 3. Target species

Cattle (cows) and pigs (sows and young females).

### 4. Indications for use

#### Cows

Indications for reproduction: synchronisation or induction of oestrus. Induction of parturition after day 270 of gestation.

Therapeutic indications: ovarian dysfunction (persistent corpus luteum, luteal cyst), endometritis/pyometra, delayed uterine involution, induction of abortion in the first half of pregnancy and expulsion of mummified foetuses.

#### Sows and young females

Indications for reproduction: induction of parturition.

### 5. Contraindications

Do not use in pregnant females, unless it is desirable to induce parturition or induction of abortion.

Do not use in sows which are expected to have a distocic parturition due to abnormal position of the foetus, mechanical obstruction, etc.

Do not use in animals suffering cardiovascular or respiratory diseases.

Do not use in animals with spastic diseases of the respiratory or gastrointestinal tract.

### 6. Special warnings

None.

#### Special precautions for safe use in the target species:

As with parenteral administration of any substance, basic antiseptic rules should be observed.

The injection site must be thoroughly cleaned and disinfected in order to reduce the risk of infection with anaerobic bacteria.

Induction of labour before the 111th day of gestation may cause mortality in piglets and an increase in the number of sows that require manual assistance.

Do not administer by intravenous route.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Prostaglandins of the F<sub>2α</sub> type can be absorbed through the skin and may cause bronchospasm or miscarriage.

Care should be taken when handling the product to avoid self-injection or skin contact.

Pregnant women, women of child-bearing age, asthmatics and people with bronchial or other respiratory problems, should avoid contact with, or wear disposable plastic gloves when administering the product.

Accidental spillage on the skin should be washed off immediately with soap and water.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Should shortness of breath result from accidental inhalation or injection, seek urgent medical advice and show the doctor this warning.

Do not eat, drink or smoke while handling the product.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

Do not use in gestating animals unless it is desirable to induce parturition or therapeutic induction of abortion.

Interaction with other medicinal products and other forms of interaction:

Do not administer the treatment together with non-steroidal anti-inflammatory drugs since they inhibit endogenous prostaglandin synthesis.

The activity of other oxytocic agents can be increased after the administration of cloprostenol.

Overdose:

At 10 times the therapeutic dose, no adverse reactions were reported. In general, a large overdose could result in the following symptoms: increased pulse and breathing rate, bronchoconstriction, increased body temperature, increased amounts of loose faeces and urine, salivation and vomiting. As no specific antidote has been identified, in the case of overdose, symptomatic therapy is advisable. An overdose will not accelerate corpus luteum regression.

Special restrictions for use and special conditions for use:

Not applicable.

Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **7. Adverse events**

Cattle (cows) and pigs (sows and young females):

|                        |  |
|------------------------|--|
| Undetermined frequency | Injection site infection <sup>a</sup> .<br>Injection site swelling <sup>a</sup> .<br>Crepitus <sup>a</sup> .<br>Retained placenta <sup>b</sup> .<br>Behavioural changes <sup>c</sup> . |
|------------------------|--|

<sup>a</sup> due to anaerobic infection, especially after intramuscular injection in cows.

<sup>b</sup> dependent on the time of treatment relative to the date of conception, the incidence in cows may be increased.

<sup>c</sup> similar to those changes associated with natural farrowing in sows usually ceasing within one hour.



Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or to the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system {national system details}.

## **8. Dosage for each species, routes and method of administration**

For intramuscular use.

### Cows

Administer 2 ml of the veterinary medicinal product, equivalent to 150 micrograms of d-cloprostenol/animal by intramuscular route. Repeat after 11 days for the synchronisation of oestrus. The dose of 2 ml equivalent to 150 micrograms of d-cloprostenol/animal by intramuscular route can be repeated for the induction of oestrus and for the treatment of ovarian dysfunction, endometritis/pyometra and delayed uterine involution.

In particular:

- Induction of oestrus (also in cows showing weak or silent heat): administer the veterinary medicinal product after having established the presence of a corpus luteum (6-18<sup>th</sup> day of the cycle); heat usually appears within 48-60 hours. Proceed, therefore, with insemination 72-96 hours after injection. If oestrus is not evident, administration of the product needs to be repeated 11 days after the first injection.
- Synchronisation of oestrus: administer the veterinary medicinal product twice, with an interval of 11 days between each dose. Proceed therefore with two artificial inseminations at intervals of 72 and 96 hours from the second injection.
- Induction of parturition: administer the veterinary medicinal product after 270 days of pregnancy. Birth usually results within 30-60 hours of treatment.
- Mummified foetus: expulsion of the foetus is observed within 3-4 days after administration of the veterinary medicinal product.
- Induction of abortion: administer the veterinary medicinal product in the first half of pregnancy.
- Ovarian dysfunction (persistent corpus luteum, luteal cysts): administer the veterinary medicinal product, then proceed to inseminate at the first oestrus after injection. If oestrus is not evident, conduct a further gynaecological examination, and repeat the injection 11 days after the first administration. Insemination must always be carried out 72-96 hours after injection.
- Endometritis, pyometra: administer the veterinary medicinal product and if necessary repeat the treatment after 10-11 days.
- Delayed uterine involution: administer the veterinary medicinal product and, if considered necessary, carry out one or two successive treatments at 24 hour intervals.

### Sows and young females

Administer 1 ml of the veterinary medicinal product, equivalent to 75 micrograms of d-cloprostenol/animal, by intramuscular route, not earlier than 112 days of pregnancy. Repeat after 6 hours. Alternatively, 20 hours after the initial dose of the veterinary medicinal product, a myometrial stimulant (oxytocin or carazolol) may be administered.

Following the protocol of the double administration, approximately 70-80% of the animals will give birth during the interval between 20 and 30 hours after the first administration.

## **9. Advice on correct administration**

As with every prostaglandin-based product, injection in contaminated skin areas is to be avoided in order to reduce the risk of infection with anaerobic bacteria.

The injection site must be thoroughly cleaned and disinfected before administration.

The closures should not be punctured more than 20 times

#### **10. Withdrawal periods**

Meat and offal:

cattle                Zero days

pigs                 1 day

Milk:                Zero hours

#### **11. Special storage precautions**

Keep out of the sight and reach of children.

Do not store above 25 °C.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp.

The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging : 28 days.

#### **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

#### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

#### **14. Marketing authorisation numbers and pack sizes**

1 vial of 2 ml + syringe    Marketing Authorisation No. :

15 vials of 2 ml            Marketing Authorisation No. :

60 vials of 2 ml            Marketing Authorisation No. :

1 vial of 10 ml             Marketing Authorisation No. :

10 vials of 10 ml          Marketing Authorisation No. :

1 vial of 20 ml             Marketing Authorisation No. :

5 vials of 20 ml            Marketing Authorisation No. :

Not all pack sizes may be marketed.

#### **15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database. (<https://medicines.health.europa.eu/veterinary>).

## **16. Contact details**

### Marketing authorisation holder and manufacturer responsible for batch release:

FATRO S.p.A.  
Via Emilia, 285  
40064 Ozzano dell'Emilia (Bologna), Italy.

### Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

## **17. Other information**

The veterinary medicinal product is a sterile aqueous solution containing 75 micrograms/ml of dextrorotatory cloprostenol, a synthetic analogue of the prostaglandin  $F_{2\alpha}$ .

d-cloprostenol, the dextrorotatory enantiomer, constitutes the biologically active component of the racemic cloprostenol molecule and results in an approximate 3.5-fold increase in activity.

Administered in the luteal phase of the oestrus cycle, d-cloprostenol induces functional and morphological regression of the corpus luteum (luteolysis) resulting in a sharp fall in progesterone levels. The increased release of the follicle stimulating hormone (FSH), induces the follicular maturation followed by signs of oestrus and by ovulation.

Pharmacokinetic studies demonstrate a rapid absorption of d-cloprostenol. The peak blood level is reached a few minutes following intramuscular administration, as well as a rapid diffusion to the ovaries and uterus, the organs in which the maximum concentration is reached 10-20 minutes after administration.

Following intramuscular administration of 150 micrograms of d-cloprostenol in the cows, the peak plasma level ( $C_{max}$ ) of 1.4 micrograms/l is reached after approximately 90 minutes, while the elimination half life ( $t_{1/2\beta}$ ) is in the order of 1 hour 37 minutes. In sows, a  $C_{max}$  of approximately 2 micrograms/l is observed between 30 and 80 minutes following administration of 75 micrograms d-cloprostenol, with an elimination half life in the order of 3 hours 10 minutes.

